Search Results

The Francis Crick Institute has repurposed its laboratory facilities to become a COVID-19 testing facility, to help combat the spread of infection and allow key workers to perform lifesaving duties and remain safe.

To mark this year’s World TB Day, we spoke to Robert Wilkinson, head of the Crick’s Tuberculosis Laboratory, about his team’s work in Africa, understanding the links between SARS-CoV-2 and TB infections.

The COVID-19 outbreak requires a concerted research effort - at the Crick researchers are looking at how the virus interacts with our body and how the virus leapt from animals to humans. 

A third ‘booster’ dose of COVID-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Wednesday) as a Research letter in The Lancet. 

Patients with blood cancers such as leukaemia vary in their immune response to COVID-19 and can struggle to clear infection for very many weeks.

Researchers at the Crick, King’s College London and Guy's and St Thomas' NHS Foundation Trust, have found a common immune signature in the blood of patients with COVID-19, which could be used to predict how severely ill a patient will become, aiding patient management. 

Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains.

Researchers at the Crick and Charité – Universitätsmedizin Berlin have identified 27 protein biomarkers that could be used to predict whether a patient with COVID-19 is likely to become severely ill with the disease.